Neumora Therapeutics, Inc. (NMRA)
(Real Time Quote from BATS)
$11.70 USD
-0.09 (-0.76%)
Updated Aug 8, 2024 12:00 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Neumora Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -235.93 | -130.90 | NA | NA | NA |
Depreciation/Amortization & Depletion | -3.07 | -0.11 | NA | NA | NA |
Net Change from Assets/Liabilities | -8.90 | -6.95 | NA | NA | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | NA | NA | NA |
Other Operating Activities | 84.62 | 23.07 | NA | NA | NA |
Net Cash From Operating Activities | -163.28 | -114.90 | NA | NA | NA |
Property & Equipment | -0.12 | -0.51 | NA | NA | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | NA | NA | NA |
Investments | 69.09 | -154.50 | NA | NA | NA |
Other Investing Activities | -4.59 | -13.00 | NA | NA | NA |
Net Cash from Investing Activities | 64.39 | -168.01 | NA | NA | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 235.74 | 116.49 | NA | NA | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | NA | NA | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | NA | NA | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | NA | NA | NA |
Other Financing Activities | -3.80 | -0.74 | NA | NA | NA |
Net Cash from Financing Activities | 231.94 | 115.74 | NA | NA | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | NA | NA | NA |
Net Change In Cash & Equivalents | 133.05 | -167.17 | NA | NA | NA |
Cash at Beginning of Period | 242.21 | 409.37 | NA | NA | NA |
Cash at End of Period | 375.25 | 242.21 | NA | NA | NA |
Diluted Net EPS | -3.63 | -4.81 | NA | NA | NA |
Fiscal Year End for Neumora Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -53.72 | -235.93 | -127.20 | NA |
Depreciation/Amortization & Depletion | NA | -0.99 | -3.07 | -2.57 | NA |
Net Change from Assets/Liabilities | NA | 3.59 | -8.90 | 4.21 | NA |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | NA | 8.16 | 84.62 | 13.71 | NA |
Net Cash From Operating Activities | NA | -42.96 | -163.28 | -111.84 | NA |
Property & Equipment | NA | 0.00 | -0.12 | -0.07 | NA |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | NA |
Investments | NA | -149.23 | 69.09 | 50.78 | NA |
Other Investing Activities | NA | -0.78 | -4.59 | 0.00 | NA |
Net Cash from Investing Activities | NA | -150.00 | 64.39 | 50.71 | NA |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 1.85 | 235.74 | 235.40 | NA |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | NA | 0.00 | -3.80 | -2.98 | NA |
Net Cash from Financing Activities | NA | 1.85 | 231.94 | 232.42 | NA |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | NA | -191.11 | 133.05 | 171.29 | NA |
Cash at Beginning of Period | NA | 375.25 | 242.21 | 242.21 | NA |
Cash at End of Period | NA | 184.14 | 375.25 | 413.50 | NA |
Diluted Net EPS | NA | -0.34 | -0.71 | -1.14 | NA |